Novel Cationic Lipid That Delivers SiRNA and Enhances Therapeutic Effect in Lung Cancer Cells

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2009 Mar 10

PMID 19267451

Citations 37

Authors

Yunching Chen

Joyeeta Sen

Surendar Reddy Bathula

Qi Yang

Raffaella Fittipaldi

Leaf Huang

Affiliations

Soon will be listed here.

Abstract

We have developed lipid-polycation-DNA (LPD) nanoparticles containing DOTAP and targeted with polyethylene glycol (PEG) tethered with anisamide (AA) to specifically deliver siRNA to H460 human lung carcinoma cells which express the sigma receptor. A novel non-glycerol based cationic lipid which contains both a guanidinium and a lysine residue as the cationic headgroup, i.e. DSGLA, downregulated pERK more efficiently in H460 cells than DOTAP. As demonstrated by using fluorescently labeled siRNA, LPD-PEG-AA prepared with DSGLA efficiently delivered siRNA to the cytoplasm of the H460 cells. Although the siRNA delivered by LPD-PEG-AA containing either DOTAP or DSGLA could effectively silence EGFR expression, a synergistic cell killing effect in promoting cellular apoptosis was only observed with DSGLA. The fluorescently labeled siRNA was efficiently delivered into the cytoplasm of H460 xenograft tumor by the LPD-PEG-AA containing either DOTAP or DSGLA 4 h after intravenous injection. Three daily injections (0.6 mg/kg) of siRNA formulated in the LPD-PEG-AA containing either DOTAP or DSGLA could effectively silence the epidermal growth factor receptor (EGFR) in the tumor, but the formulation containing DSGLA could induce more cellular apoptosis. A significant improvement in tumor growth inhibition was observed after dosing with LPD-PEG-AA containing DSGLA. Thus, DSGLA served as both a formulation component as well as a therapeutic agent which synergistically enhanced the activity of siRNA.

Citing Articles

In vivo biodistribution and ototoxicity assessment of cationic liposomal-ceftriaxone via noninvasive trans-tympanic delivery in chinchilla models: Implications for otitis media therapy.

Shafiee S, Hong W, Lucas J, Khampang P, Runge C, Wells C Int J Pediatr Otorhinolaryngol. 2024; 178:111894.

PMID: 38350381 PMC: 10939715. DOI: 10.1016/j.ijporl.2024.111894.

Lipid nanovehicles overcome barriers to systemic RNA delivery: Lipid components, fabrication methods, and rational design.

Yan J, Zhang H, Li G, Su J, Wei Y, Xu C Acta Pharm Sin B. 2024; 14(2):579-601.

PMID: 38322344 PMC: 10840434. DOI: 10.1016/j.apsb.2023.10.012.

Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications.

Dhayalan M, Wang W, Riyaz S, Dinesh R, Shanmugam J, Irudayaraj S 3 Biotech. 2024; 14(2):57.

PMID: 38298556 PMC: 10825110. DOI: 10.1007/s13205-023-03901-8.

Lipid-Based Inhalable Micro- and Nanocarriers of Active Agents for Treating Non-Small-Cell Lung Cancer.

Gandhi S, Roy I Pharmaceutics. 2023; 15(5).

PMID: 37242697 PMC: 10223242. DOI: 10.3390/pharmaceutics15051457.

Spermidine/Spermine N1-Acetyltransferase 1 ()-A Potential Gene Target for Selective Sensitization of Glioblastoma Cells Using an Ionizable Lipid Nanoparticle to Deliver siRNA.

Yathindranath V, Safa N, Sajesh B, Schwinghamer K, Vanan M, Bux R Cancers (Basel). 2022; 14(21).

PMID: 36358597 PMC: 9656607. DOI: 10.3390/cancers14215179.

References

Liu W, Cheng Y, Chang L . ROS-mediated p38alpha MAPK activation and ERK inactivation responsible for upregulation of Fas and FasL and autocrine Fas-mediated cell death in Taiwan cobra phospholipase A(2)-treated U937 cells. J Cell Physiol. 2009; 219(3):642-51. DOI: 10.1002/jcp.21713. View

Loeffler M, Daugas E, Susin S, Zamzami N, Metivier D, Nieminen A . Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. FASEB J. 2001; 15(3):758-67. DOI: 10.1096/fj.00-0388com. View

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

Klouz A, Ben Said D, Ferchichi H, Kourda N, Ouanes L, Lakhal M . Protection of cellular and mitochondrial functions against liver ischemia by N-benzyl-N'-(2-hydroxy-3,4-dimethoxybenzyl)-piperazine (BHDP), a sigma1 ligand. Eur J Pharmacol. 2007; 578(2-3):292-9. DOI: 10.1016/j.ejphar.2007.09.038. View

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

Qian H, Yu J, Li Y, Wang H, Song C, Zhang X . RNA interference of metastasis-associated gene 1 inhibits metastasis of B16F10 melanoma cells in a C57BL/6 mouse model. Biol Cell. 2007; 99(10):573-81. DOI: 10.1042/bc20060130. View

Bajaj A, Kondaiah P, Bhattacharya S . Synthesis and gene transfer activities of novel serum compatible cholesterol-based gemini lipids possessing oxyethylene-type spacers. Bioconjug Chem. 2007; 18(5):1537-46. DOI: 10.1021/bc070010q. View

Tong A . Small RNAs and non-small cell lung cancer. Curr Mol Med. 2006; 6(3):339-49. DOI: 10.2174/156652406776894554. View

Daugas E, Susin S, Zamzami N, Ferri K, Irinopoulou T, Larochette N . Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J. 2000; 14(5):729-39. View

10.

Navolanic P, Steelman L, McCubrey J . EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol. 2003; 22(2):237-52. View

11.

Ivanov V, Hei T . Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene. 2004; 24(4):616-26. PMC: 4394621. DOI: 10.1038/sj.onc.1208125. View

12.

Vilner B, John C, Bowen W . Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995; 55(2):408-13. View

13.

Lechardeur D, Lukacs G . Intracellular barriers to non-viral gene transfer. Curr Gene Ther. 2002; 2(2):183-94. DOI: 10.2174/1566523024605609. View

14.

Yan W, Chen W, Huang L . Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J Control Release. 2008; 130(1):22-8. DOI: 10.1016/j.jconrel.2008.05.005. View

15.

Geusens B, Lambert J, De Smedt S, Buyens K, Sanders N, Van Gele M . Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes. J Control Release. 2008; 133(3):214-20. DOI: 10.1016/j.jconrel.2008.10.003. View

16.

Kim H, Moon J, Kim K, Choi M, Lee J, Heo Y . Gene-transferring efficiencies of novel diamino cationic lipids with varied hydrocarbon chains. Bioconjug Chem. 2004; 15(5):1095-101. DOI: 10.1021/bc049934t. View

17.

Lorenzo H, Susin S, Penninger J, Kroemer G . Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ. 1999; 6(6):516-24. DOI: 10.1038/sj.cdd.4400527. View

18.

Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y . Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm. 2004; 277(1-2):39-61. DOI: 10.1016/j.ijpharm.2003.09.050. View

19.

Saraswat Ohri S, Vashishta A, Proctor M, Fusek M, Vetvicka V . Depletion of procathepsin D gene expression by RNA interference: a potential therapeutic target for breast cancer. Cancer Biol Ther. 2007; 6(7):1081-7. DOI: 10.4161/cbt.6.7.4325. View

20.

Fleury C, Mignotte B, Vayssiere J . Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 2002; 84(2-3):131-41. DOI: 10.1016/s0300-9084(02)01369-x. View